前收市價 | 17.25 |
開市 | 無 |
買盤 | 13.00 |
賣出價 | 22.00 |
拍板 | 720.00 |
到期日 | 2026-06-18 |
今日波幅 | 17.25 - 17.25 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 4 |
The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
The latest bull market has plenty of intriguing buying opportunities.
Growth stocks with wide moats and strong financials can compound investor returns with time.